

Differences in the fecal Microbiome Before and After Colorectal Cancer Treatment

Running Title: Human Microbiome and Colorectal Cancer

Marc A Sze¹, Nielson T Baxter², Mack T Ruffin IV³, Mary AM Rogers², and Patrick D Schloss^{1†}

† To whom correspondence should be addressed: pschloss@umich.edu

¹ Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI

² Department of Internal Medicine, University of Michigan, Ann Arbor, MI

³ Department of Family Medicine and Community Medicine, Penn State Hershey Medical Center, Hershey, PA

Abstract

Background: Colorectal cancer (CRC) continues to be a worldwide health problem with previous research suggesting that a link may exist between the fecal bacterial microbiome and CRC. The overall objective of our study was to test the hypothesis that changes in the bacterial microbiome occur after lesion (i.e. adenoma or carcinoma) removal. Specifically, we wanted to identify what within the community was different before and after removal of said lesion.

Results: The bacterial microbiome in pre and post surgery samples for the adenoma group were more similar to each other than the carcinoma group ($P\text{-value} < 0.05$). There was no difference for either the adenoma or carcinoma group in the relative abundance of any OTU between the pre and post lesion removal ($P\text{-value} > 0.05$). A model built to classify model built to classify lesion had an AUC range of 0.811 - 0.866 while a model built to classify initial versus follow up samples had an AUC range of 0.641 - 0.805. The post removal sample for both models had a decrease in the positive probability for either lesion or initial sample ($P\text{-value} < 0.05$). The lesion model used a total of 53 variables while the initial sample model used a total of 70 variables. A total of 23 OTUs were common to both models with the majority of these classifying to commensal bacteria (e.g. *Bacteroides*, *Clostridiales*, *Blautia*, and *Ruminococcaceae*).

Conclusions: Our data supports the hypothesis that there are differences in the bacterial microbiome between pre and post lesion removal samples. With individuals with carcinoma having more drastic differences to the overall community than those with adenoma. Changes to commensal bacteria were some of the most important variables for model classification, suggesting that these bacteria may be central to initial polyp formation and transition to carcinoma.

25 **Keywords**

26 bacterial microbiome; colorectal cancer; polyps; FIT; post surgery; risk factors

Background

Colorectal cancer (CRC) continues to be a leading cause of cancer related deaths and is currently the third most common cause of cancer deaths [1,2]. Over the last few years death due to the disease has seen a significant decrease, thanks mainly to improvements in screening [1]. However, despite this improvement there are still approximately 50,000 deaths from the disease a year [2].

Recently, there has been promising work on the bacterial microbiome and it's ability to complement existing screening methods such as Fecal Immunoglobulin Test (FIT) or act alone as a screening tool [3,4]. There has also been research into how the bacterial microbiome could be altered directly on tumor tissue itself [5]. A few studies have also shown how this microbiome [6] or specific members within it [7] could be directly involved with the pathogenesis of CRC. These studies have helped to provide a tantalizing link between the bacterial microbiome and CRC. Although these studies suggest that the bacterial microbiome might change after treatment there remains limited information on the bacterial microbiome before and after surgical removal of lesion (adenoma or carcinoma) and whether the community changes at all.

In this study we tested the hypothesis that the bacterial microbiome changes between pre (initial) and post (follow up) samples after removal of a lesion (adenoma or carcinoma). Our analysis included both alpha and beta diversity analysis along with investigation of individual operational taxonomic units (OTUs). We also utilized Random Forest to build models to classify either initial and follow up samples or lesion and normal samples and then subsequently observe how these models, as well as specific OTUs within them, performed pre and post surgery. We also investigated the models for similar important OTUs to identify the crucial OTUs for not only classifying initial and follow up samples but also lesion or normal.

Results

Bacterial Community and FIT: We first wanted to test whether there were any broad differences between initial and follow up samples based on lesion being either adenoma or carcinoma. What we found was that the bacterial community in those with carcinoma were more dissimilar (as measured by thetacyc) to their initial sample than those with adenoma (P-value < 0.001) [Figure 1a]. We also found that there were larger changes in fecal blood (measured by FIT) for those with carcinoma versus adenoma (P-value < 0.0001) [Figure 1b]. The broad shift in bacterial community structure before and after surgery was visualized using NMDS for both adenoma [Figure 1c] (PERMANOVA > 0.05) and carcinoma [Figure 1d] (PERMANOVA < 0.05). Interestingly, when initial and follow up samples were compared to each other, regardless of whether they were adenoma or carcinoma (lesion), there was no significant overall difference between them (PERMANOVA > 0.05). When investigating more broad alpha diversity metrics there was no difference found between initial and follow up samples for lesion, adenoma only, or carcinoma only for any metric tested [Table S1]. We also observed that there was no difference in OTU relative abundance between initial and follow up samples for lesion, adenoma only, or carcinoma only [Figure S1].

Carcinoma Associated Bacteria: Previous literature has suggested that a number of oral microbes may be important in CRC pathogenesis [8]. So we next examined whether there were differences in previously well described carcinoma associated OTUs. These included the OTUs that aligned with *Porphyromonas asaccharolytica* (Otu000202), *Fusobacterium nucleatum* (Otu000442), *Parvimonas micra* (Otu001273), and *Peptostreptococcus stomatis* (Otu001682). There was a decrease in relative abundance in initial and follow up samples for lesion and carcinoma for *Parvimonas micra* (P-value < 0.05), and *Porphyromonas asaccharolytica* (P-value < 0.05) [Figure 2A]. In contrast, there was no difference in relative abundance in any of these OTUs for those with adenoma [Figure 2B]. We also observed

that only a small percentage of those with adenoma or carcinoma were positive or had an appreciable relative abundance of any of these respective OTUs [Figure 2].

The Lesion Model: We next wanted to identify if there were any common bacterial microbiome changes in individuals with adenoma or carcinoma versus normal control individuals. We investigated this by creating a model to classify lesion versus normal based on the bacterial community and FIT measurements. This model had an AUC range of 0.811 - 0.866 after 100 iterations of 20 repeated 10-fold cross validations. The ROC curve for the final lesion model used was within the observed range of the 100 different test set AUC iterations [Figure 3A]. There were a total of 53 variables [Figure 3B]. For this model FIT measurement resulted in the largest decrease in MDA while the OTU with the largest MDA was *Lachnospiraceae* (Otu000015) [Figure 3B].

If there were common OTUs that could separate adenoma and carcinoma from normal controls, we would expect to find a decrease in the positive probability of the follow up sample to be a lesion. This is what we observed for the lesion model (P-value < 0.001). When we separated individuals based on whether they had an adenoma or carcinoma there was only a decrease in positive probability for the carcinoma group [Figure 3C] (P-value < 0.001) and not for the adenoma group [Figure 3D] (P-value > 0.05). We also observed that there were no significant differences in whether the models classified the samples as having lesion between the predicted and actual (P-value > 0.05). The lesion model was able to correctly classify the one individual who still had a carcinoma on follow up [Figure 3C].

The Initial Sample Model: After building a model to classify based on lesion we wanted to then build a separate model specifically to be able to classify whether samples were initial or follow up samples based on the bacterial community and FIT measurements. The initial sample model had an AUC range of 0.641 to 0.805 after 100 iterations of 20 repeated 10-fold cross validations. The test set AUC range for this model performed better than the

training set AUCs. There was a marked decrease in the ROC curve for the final model used when compared to the 100 test set AUC iterations [Figure 4A]. There were a total of 70 variables [Figure 4B]. For this model *Pseudomonas* (Otu000438) resulted in the largest decrease in MDA while FIT measurement resulted in the sixth largest decrease in MDA [Figure 4B].

If there were common OTUs that could separate initial from follow up sample regardless of whether the lesion was adenoma or carcinoma we would expect to find a decrease in the positive probability of the follow up sample to be an initial sample. This is what we observed for the initial sample model (P-value < 0.001). When we separated individuals based on whether they had an adenoma or carcinoma there was a decrease in positive probability for both the carcinoma group [Figure 4C] (P-value < 0.001) and for the adenoma group [Figure 4D] (P-value < 0.001). For this model there was no difference between the predicted and actual classifications (P-value > 0.05).

Common OTUs to both Models: We next wanted to compare the similarity between the OTU variables used in either model. The main purpose was to identify which OTUs were important not only for the classification of lesion but also for the classification of initial or follow up sample. Potentially, these specific OTUs are the most important with respect to the bacterial microbiome response to removal of lesion. When we compared the two different models with each other there were a total of 23 common OTUs. Some of the most common taxonomic identifications belonged to *Bacteroides*, *Clostridiales*, *Blautia*, and *Ruminococcaceae*. The vast majority of these OTUs had classifications to bacteria typically thought of as commensal [Table S2].

Treatment Differences: After observing these changes in the bacterial community and positive probability we wanted to assess whether additional treatments, such as chemotherapy and radiation, could have an impact on the results that we observed. There was only a significant difference for change in positive probability for those treated with

130 chemotherapy for the initial sample model (P-value < 0.05). All other variables that were
131 tested showed no difference based on whether chemotherapy or radiation was used [Table
132 S3].

Discussion

From our results there were large observed differences in the bacterial microbiome between pre and post surgery samples based on whether the individual had an adenoma or carcinoma. There were much larger differences between initial and follow up samples based on the thetayc distance metric and in fecal blood as measured by FIT for individuals with carcinoma versus adenoma [Figure 1]. However, there were no differences between initial and follow up samples for Shannon Diversity, observed OTUs, or evenness regardless of whether the individual had an adenoma or carcinoma [Table S1]. There was also no differences in relative abundance of any specific OTU for lesion, adenoma only, or carcinoma only [Figure s1]. Although there was a detectable change in the carcinoma group and this change was towards what would be expected for normal controls, the follow up samples may not be a completely normal bacterial microbiome.

Although there were no differences when investigating all OTUs, when looking specifically at four OTUs that taxonomically classified to previously suggested carcinoma associated microbes we found that only 2/4 had a decrease in relative abundance between initial and follow up for those with carcinoma and 0/4 had differences for those with adenoma. This data would suggest that these specific OTUs may be important in the transition of an adenoma to a carcinoma but less so in the initiation of an adenoma from benign tissue.

We next created a model that incorporated FIT and the bacterial microbiome to be able to classify lesions (adenoma or carcinoma). What we found was that not only was the positive probability of a lesion reduced after lesion removal [Figure 4 & S4] but also that the commonly associated CRC bacteria were not highly represented within this model. Rather, OTUs that made up the most important variables overwhelmingly belonged to commensal bacteria. With only a single OTU from a previously associated cancer bacterium (*Porphyromonas asaccharolytica*). We followed this up by creating a second

model to classify initial versus follow up samples. We found that this model was able to accurately classify initial versus follow up samples [Figure 4 & S4]. Providing additional information on the importance of commensal bacteria was that there were a total of 23 OTUs in common to both models and the vast majority belonged to regular residents of our gut community [Table S3].

For the majority of tests performed there were no differences in the bacterial microbiome based on whether chemotherapy or radiation was received [Table S3]. Within our study there was a significant difference for the time elapsed in the collection of the follow up sample between adenoma and carcinoma (uncorrected P-value < 0.05), with time passed being less for adenoma (253 +/- 41.3 days) then carcinoma (351 +/- 102 days). These results would indicate that the findings described were specific to the surgical intervention and that some of the differences observed between carcinoma and adenoma samples could be due to differences in collection time between samples for the two different groups. For time differences, specifically, it could confound the observation that carcinomas changed more than adenomas [Figure 1a & 1d].

This study builds upon previous work from numerous labs that have looked into the bacterial microbiome as a potential screening tool [3,4,9–11] by exploring what happens to the bacterial community after surgical removal of a lesion. Based on previous work by Arthur, et al. [12] it may not be surprising to have E.coli as one of the most important OTUs and one that was common to both models. Interestingly, many of the most important OTUs had taxonomic identification for resident gut microbes. This could suggest that the bacterial community is one of the first components that could change during the pathogenesis of disease. These bacterial microbiome changes could be the first step in allowing more inflammatory bacterium to gain a foothold within the colon [8].

Curiously, we observed that the typical CRC associated bacteria were not predictive within our models. There are a number of reasons why this may have occurred. First, is that they

were not present in enough individuals to be able to classify those with and without disease with a high degree of accuracy. Second, is that our Random Forest models were able to gather the same information from measures such as FIT or other OTUs. It is also possible that both of these explanations could have played a role. Regardless, our observations would suggest that an individual's resident bacteria have a large role to play in disease initiation and could change in a way that allows predictive models to lower the positive probability of a lesion after surgery [Figure 4]. It should be noted that our study does not argue against the importance of these CRC associated bacteria in the pathogenesis of disease but rather that they are not the main bacteria changing after surgical removal of lesion. In fact, it is possible that these CRC associated bacteria are important in the transition from adenoma to carcinoma and would be one explanation as to why in our data we not only see high initial relative abundances in carcinoma and not adenoma individuals but also large decreases in relative abundance in some of those with carcinoma but not in those with adenoma after surgery [Figure 2].

Many of the common OTUs between the different models used had many OTUs that taxonomically classified to potential butyrate producers [Table S2]. Another batch of OTUs classified to bacteria that can either degrade polyphenols or are inhibited by them. Both butyrate and polyphenols are thought to be protective against cancer in part by reducing inflammation [13]. These protective compounds are derived from the breakdown of fiber, fruits, and vegetables by resident gut microbes. One example of this potential diet-microbiome-inflammation-polyp axis is that *Bacteroides*, which was highly prevalent in our models, are known to be increased in those with high non-meat based protein consumption [14]. High protein consumption in general has been linked with an increased CRC risk [15]. Conversely, *Bacteroides* are inhibited by polyphenols which are derived from fruits and vegetables [16]. Our data fits with the hypothesis that the microbial metabolites from breakdown products within our own diet could not only help to shape the existing community but also have an effect on CRC risk and disease progression.

One limitation of our study is that we do not know whether individuals who were still classified as positive by the lesion model eventually had a subsequent CRC diagnosis. This information would help to strengthen the case for our lesion model keeping a number of individuals above the cutoff threshold even though at follow up they were diagnosed as no longer having a lesion. Another limitation is that we do not know if adding modern tests such as the stool DNA test [17] could help improve our overall AUC. This study also drew heavily from those with Caucasian ancestry making it possible that the observations may not be representative of those with either Asian or African ancestry. Although our training and test set are relatively large we still run the risk of over-fitting or having a model that may not be representative of other populations. We've done our best to safeguard against this by not only running 10-fold cross validation but also having over 100 different 80/20 splits to try and mimic the type of variation that might be expected to occur. The time difference in collection of sample between adenoma and carcinoma could have affected our observations for differences between individuals with adenoma or carcinoma. This confounding though would not affect the observations where these individuals are grouped together.

Interestingly, within figure 3 the before sample model showed better test AUC results than the training set AUC. This may have occurred because the training AUC determined from 20 repeated 10 fold cross validation removed samples at random and did not take into account that they were matched samples. Another potential reason is that the model itself may be over-fit since the total number of samples was not that large. However, the lesion model did not suffer from these discrepancies and similar conclusions can be drawn solely from this model alone. Further independent studies need to be carried out to verify our findings since not only are we dealing with feces, which could be very different than the communities present on the actual tissue, but also are dealing with correlations that may not be representative of the true pathogenesis of disease.

237 Despite these limitations our findings add to the existing scientific knowledge on CRC and
238 the bacterial microbiome: That there is a measurable difference in the bacterial community
239 after surgical removal of lesion. Further, the ability for machine learning algorithms to
240 take bacterial microbiome data and successfully lower positive probability after either
241 adenoma or carcinoma removal provides evidence that there are specific signatures,
242 mostly attributable to commensal organisms, associated with these lesions. Our data
243 provides evidence that commensal bacteria may be important in the development of polyps
244 and also potentially the transition from adenoma to carcinoma.

Methods

Study Design and Patient Sampling: The sampling and design were similar to that reported in Baxter, et al [3]. In brief, study exclusion involved those who had already undergone surgery, radiation, or chemotherapy, had colorectal cancer before a baseline fecal sample could be obtained, had IBD, a known hereditary non-polyposis colorectal cancer, or Familial adenomatous polyposis. Samples used to build the models for prediction were collected either prior to a colonoscopy or between 1 - 2 weeks after. The bacterial microbiome has been shown to normalize within this time period [18]. Our follow up data set had a total of 67 individuals that not only had a sample as described but also a follow up sample between 188 - 546 days after surgery and treatment had been completed. This study was approved by the University of Michigan Institutional Review Board. All study participants provided informed consent and the study itself conformed to the guidelines set out by the Helsinki Declaration.

FIT and 16S rRNA Gene Sequencing: FIT was analyzed as previously published using both OC FIT-CHEK and OC-Auto Micro 80 automated system (Polymedco Inc.) [19]. 16S rRNA gene sequencing was completed as previously described by Kozich, et al. [20]. DNA extraction used the 96 well Soil DNA isolation kit (MO BIO Laboratories) and an epMotion 5075 automated pipetting system (Eppendorf). The V4 variable region was amplified and the resulting product was split between three sequencing runs with normal, adenoma, and carcinoma evenly represented on each run. Each group was randomly assigned to avoid biases based on sample collection location.

Sequence Processing: The mothur software package (v1.37.5) was used to process the 16S rRNA gene sequences. This process has been previously described [20]. The general processing workflow using mothur was as follows: Paired-end reads were first merged into contigs, quality filtered, aligned to the SILVA database, screened for chimeras,

classified with a naive Bayesian classifier using the Ribosomal Database Project (RDP), and clustered into Operational Taxonomic Units (OTUs) using a 97% similarity cutoff with an average neighbor clustering algorithm. The number of sequences for each sample was rarefied to 10523 in an attempt to minimize uneven sampling.

Lesion Model Creation: The Random Forest [21] algorithm was used to create the model used for prediction of lesion (adenoma or carcinoma) with the main testing and training of the model completed on a data set of 423 individuals. This model was then applied to our follow up data set of 67 individuals. In brief, the model included data on FIT and the bacterial microbiome. Non-binary data was checked for near zero variance and OTUs that had near zero variance were removed. This pre-processing was performed with the R package caret (v6.0.73). Optimization of the mtry hyper-parameter involved taking the samples and making 100 different 80/20 (train/test) splits of the data where normal and lesion were represented in the same proportion within both the whole data set and the 80/20 split. Each of these splits were then run through 20 repeated 10-fold cross validations to optimize the mtry hyper-parameter by maximizing the AUC (Area Under the Curve of the Receiver Operator Characteristic). This resulting model was then tested on the 20% of the data that was originally held out from this overall process. Once the ideal mtry was found the entire 423 sample set was used to create the final Random Forest model on which classifications on the 67-person cohort was completed. The default cutoff of 0.5 was used as the threshold to classify individuals as positive or negative for lesion. The hyper-parameter, mtry, defines the number of variables to investigate at each split before a new division of the data is created with the Random Forest model.

Initial Sample Model Creation: We also investigated whether a model could be created that could identify pre (initial) and post (follow up) surgery samples. The main difference was that only the 67-person cohort was used at all stages of model building and classification. Other than this difference the creation of this model and optimization of

the mtry hyper-parameter was completed using the same procedure as was used for the lesion model. Instead of classifying samples as positive or negative of lesion this model classified samples as positive or negative for being an initial surgery sample.

Selection of Important OTUs: In order to assess which variables were most important to either model we counted the number of times a variable was present in the top 10% of mean decrease in accuracy (MDA) for each of the 100 different 80/20 split models and then filtered this list to variables that were only present more than 50% of the time. This final collated list of variables was what was considered the most important for the lesion or before sample models.

Statistical Analysis: The R software package (v3.3.2) was used for all statistical analysis. Comparisons between bacterial community structure utilized PERMANOVA [22] in the vegan package (v2.4.1). Comparisons between probabilities as well as overall OTU differences between initial and follow up samples utilized a paired Wilcoxon ranked sum test. Where multiple comparison testing was appropriate a Benjamini-Hochberg (BH) correction was applied [23] and a corrected P-value of less than 0.05 was considered significant. Unless otherwise stated the P-values reported are those that were BH corrected.

Analysis Overview: We first wanted to test if there were any differences based on whether the individual had an adenoma or carcinoma. This was done by testing initial and follow up samples for differences in alpha and beta diversity, testing differences in FIT between initial and follow ups, testing all OTUs that were used in either built model, and investigating the relative abundance of specific previously associated CRC bacteria (*Fusobacterium nucleatum*, *Parvimonas micra*, *Peptostreptococcus assacharolytica*, and *Porphyromonas stomatis*) based on adenoma and carcinoma. From here the lesion model was then tested for accuracy in prediction and whether it reduced the positive probability of lesion after surgery. The most important OTUs for this were used to build a reduced model and it was

assessed for similarity to the original model. We then used the initial sample model to assess whether it could classify samples better than the lesion model. The most important OTUs were then identified from this model and used to create a reduced feature initial sample model. This reduced feature model, as was done with the lesion model, was compared to the full model for loss of accuracy. A list of common OTUs were found for the two different models used. Finally, both lesion and initial sample models initial positive probabilities were tested against the follow up positive probabilities.

Reproducible Methods: A detailed and reproducible description of how the data were processed and analyzed can be found at https://github.com/SchlossLab/Size_followUps_2017. Raw sequences have been deposited into the NCBI Sequence Read Archive (SRP062005 and SRP096978) and the necessary metadata can be found at <https://www.ncbi.nlm.nih.gov/Traces/study/> and searching the respective SRA study accession.

Figure 1: General Differences between the Adenoma or Carcinoma Group. A) A significant difference was found between the adenoma and carcinoma group for thetacyc (P-value = 0.000472). B) A significant difference was found between the adenoma and carcinoma group for change in FIT measurement (P-value = 2.15e-05). C) NMDS of the initial and follow up samples for the Adenoma group. D) NMDS of the initial and follow up samples for the Carcinoma group. For C) and D) the teal represents initial samples and the pink represents follow up samples.

Figure 2: Previously Associated CRC Bacteria in Initial and Follow up Samples. A) Carcinoma initial and follow up samples had an observed significant difference in initial and follow up sample for the OTUs classified as *Parvimonas micra* (P-value = 0.0116) and *Porphyromonas asaccharolytica* (P-value = 0.00842). B) Adenoma initial and follow up samples. There were no significant differences between initial and follow up.

Figure 3: Receiver Operating Characteristic Curve for Lesion and Initial Sample Models. The shaded areas represents the range of values of a 100 different 80/20 splits of the test set data using either all variables (grey) or reduced variable (red) models. The blue line represents the reduced variable model using 100% of the data set and what was used for subsequent classification. A) Lesion model. B) Before sample model

Figure 4: Breakdown by Carcinoma and Adenoma of Prediction Results for Lesion and Initial Sample Reduced Variable Models A) Lesion positive probability change from initial to follow up sample in those with carcinoma B) Initial positive probability change from initial to follow up sample in those with carcinoma C) Lesion positive probability change from initial to follow up sample if those with adenoma or Screen Relevant Neoplasia (SRN). D) Initial positive probability change from initial to follow up sample in those with adenoma or SRN. The dotted line represents the threshold used to make the decision of whether a sample was positive or not.

Figure S1: Distribution of P-values from Paired Wilcoxon Analysis of All OTUs for Initial versus Follow Up

Figure S2: Summary of Important Variables in the Lesion Model A) MDA of the most important variables in the lesion model. The black point represents the median and the different colors are the different runs up to 100. B) The total number of appearances of each variable in the 100 different lesion models. The cutoff of 50% was used to assess importance.

Figure S3: Summary of Important Variables in Before Sample Model A) MDA of the most important variables in the lesion model. The black point represents the median and the different colors are the different runs up to 100. B) The total number of appearances of each variable in the 100 different lesion models. The cutoff of 50% was used to assess importance.

Figure S4: Breakdown by Carcinoma and Adenoma of Prediction Results for Lesion and Before Sample Full Variable Models A) Lesion positive probability change from initial to follow up sample in those with carcinoma B) Initial positive probability change from initial to follow up sample in those with carcinoma C) Lesion positive probability change from initial to follow up sample in those with adenoma or Screen Relevant Neoplasia (SRN). D) Initial positive probability change from initial to follow up sample in those with adenoma or SRN. The dotted line represents the threshold used to make the decision of whether a sample was positive or not.

Figure S5: Thetayc Versus Time of Follow up Sample from Initial

Declarations

Ethics approval and consent to participate

Consent for publication

Availability of data and material

Competing Interests

All authors declare that they do not have any relevant competing interests to report.

Funding

This study was supported by funding from the National Institutes of Health to P. Schloss (R01GM099514, P30DK034933) and to the Early Detection Research Network (U01CA86400).

Authors' contributions

All authors were involved in the conception and design of the study. MAS analyzed the data. NTB processed samples and analyzed the data. All authors interpreted the data. MAS and PDS wrote the manuscript. All authors reviewed and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors thank the Great Lakes-New England Early Detection Research Network for providing the fecal samples that were used in this study. We would also like to thank Amanda Elmore for reviewing and correcting code error and providing feedback on manuscript drafts. We would also like to thank Nicholas Lesniak for providing feedback on manuscript drafts.

References

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA: a cancer journal for clinicians*. 2010;60:277–300.
2. Hagggar FA, Boushey RP. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. *Clinics in Colon and Rectal Surgery*. 2009;22:191–7.
3. Baxter NT, Ruffin MT, Rogers MAM, Schloss PD. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome Medicine*. 2016;8:37.
4. Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. *Molecular Systems Biology*. 2014;10:766.
5. Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111:18321–6.
6. Zackular JP, Baxter NT, Chen GY, Schloss PD. Manipulation of the Gut Microbiota Reveals Role in Colon Tumorigenesis. *mSphere*. 2016;1.
7. Arthur JC, Gharaibeh RZ, Mühlbauer M, Perez-Chanona E, Uronis JM, McCafferty J, et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. *Nature Communications*. 2014;5:4724.
8. Flynn KJ, Baxter NT, Schloss PD. Metabolic and Community Synergy of Oral Bacteria in Colorectal Cancer. *mSphere*. 2016;1.
9. Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, et al. Metagenomic analysis of

faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer.
Gut. 2017;66:70–8.

10. Zackular JP, Rogers MAM, Ruffin MT, Schloss PD. The human gut microbiome as
a screening tool for colorectal cancer. Cancer Prevention Research (Philadelphia, Pa.).
2014;7:1112–21.

11. Warren RL, Freeman DJ, Pleasance S, Watson P, Moore RA, Cochrane K, et al.
Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome. 2013;1:16.

12. Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, et al.
Intestinal inflammation targets cancer-inducing activity of the microbiota. Science (New
York, N.Y.). 2012;338:120–3.

13. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal
cancer. Nature Reviews Microbiology [Internet]. 2014 [cited 2017 Feb 14];12:661–72.
Available from: <http://www.nature.com/doifinder/10.1038/nrmicro3344>

14. Zhu Y, Lin X, Li H, Li Y, Shi X, Zhao F, et al. Intake of Meat Proteins Substantially
Increased the Relative Abundance of Genus Lactobacillus in Rat Feces. PloS One.
2016;11:e0152678.

15. Mu C, Yang Y, Luo Z, Guan L, Zhu W. The Colonic Microbiome and Epithelial
Transcriptome Are Altered in Rats Fed a High-Protein Diet Compared with a Normal-Protein
Diet. The Journal of Nutrition. 2016;146:474–83.

16. Ozdal T, Sela DA, Xiao J, Boyacioglu D, Chen F, Capanoglu E. The Reciprocal
Interactions between Polyphenols and Gut Microbiota and Effects on Bioaccessibility.
Nutrients [Internet]. 2016 [cited 2017 Feb 14];8:78. Available from: <http://www.mdpi.com/>

2072-6643/8/2/78

17. Cotter TG, Burger KN, Devens ME, Simonson JA, Lowrie KL, Heigh RI, et al. Long-Term Follow-up of Patients Having False Positive Multi-target Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study. *Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research*, Cosponsored by the American Society of Preventive Oncology. 2016;

18. O'Brien CL, Allison GE, Grimpen F, Pavli P. Impact of colonoscopy bowel preparation on intestinal microbiota. *PloS One*. 2013;8:e62815.

19. Daly JM, Bay CP, Levy BT. Evaluation of fecal immunochemical tests for colorectal cancer screening. *Journal of Primary Care & Community Health*. 2013;4:245–50.

20. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. *Applied and Environmental Microbiology*. 2013;79:5112–20.

21. Breiman L. Random Forests. *Machine Learning* [Internet]. 2001 [cited 2013 Feb 7];45:5–32. Available from: <http://link.springer.com/article/10.1023/A%3A1010933404324>
<http://link.springer.com/article/10.1023%2FA%3A1010933404324?LI=true>

22. Anderson MJ, Walsh DCI. PERMANOVA, ANOSIM, and the Mantel test in the face of heterogeneous dispersions: What null hypothesis are you testing? *Ecological Monographs* [Internet]. 2013 [cited 2017 Jan 5];83:557–74. Available from: <http://doi.wiley.com/10.1890/12-2010.1>

23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B (Methodological)*. 1995;57:289–300.